The role of trefoil factor family in apparently healthy subjects administrated gastroprotective agents for the primary prevention of gastrointestinal injuries from low-dose acetylsalicylic acid: A preliminary study

Journal of Clinical Biochemistry and Nutrition

Volumn 49, Issue 2, 2011, Pages 136-140

  Kawai, Takashi ^a   Takagi, Yu ^b   Fukuzawa, Mari ^a   Yamagishi, Tetsuya ^a   Goto, Shinya ^c  

^a TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Low dose ASA; Proton pump inhibitor; Rebamipide; Transnasal endoscopy; Trefoil factor

Indexed keywords

ACETYLSALICYLIC ACID; INTESTINAL TREFOIL FACTOR; OMEPRAZOLE; PLACEBO; REBAMIPIDE; TREFOIL FACTOR FAMILY; TREFOIL FACTOR FAMILY 1; TREFOIL FACTOR FAMILY 2; TREFOIL FACTOR FAMILY 3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DIGESTIVE SYSTEM INJURY; DOUBLE BLIND PROCEDURE; ENDOSCOPY; ERYTHEMA; FEMALE; HUMAN; LOW DRUG DOSE; MALE; NORMAL HUMAN; PETECHIA; PRIMARY PREVENTION; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STOMACH MUCOSA; STOMACH PROTECTION; UNSPECIFIED SIDE EFFECT;

LOTUS;

EID: 80052042806     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.11-10     Document Type: Article

References (41)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systemic analysis of population health data. Lancet 2006; 367: 1747-1757.
2. Mehta P. Aspirin in the prophylaxis of coronary artery disease. Curr Opin Cardiol 2002; 17: 552-558. (Pubitemid 35265795)
3. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008; 51: 1829-1843. (Pubitemid 351615246)
4. Bhatt DL, Steg PG, Ohman EM, et al. REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180-189.
5. Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective dose of aspirin. Aliment Pharmacol Ther 2005; 22: 795-801. (Pubitemid 41564359)
6. Nema H, Kato M, Katsurada T, et al. Endoscopic survey of low-dose-aspirin-induced gastroduodenal mucosal injuries in patients with ischemic heart disease. J Gastroenterol Hepatol 2008; 23: S234-S236.
7. Rostom A, Dube C, Wells G, et al. Prevention NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002; 4: CD002296.
8. Shiotani A, Sakakibara T, Yamanaka Y, et al. The preventive factors for aspirin-induced peptic ulcer: aspirin ulcer and corpus atrophy. J Gastroenterol 2009; 44: 717-725.
9. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241-249.
10. Park SH, Cho CS, Lee OY, et al. Comparison of prevention of NSAID-induced gastrointestinal complications by rebamipide and misoprostol: a randomized, multicenter, controlled trial-STORM STUDY. J Clin Biochem Nutr 2007; 40: 148-155.
11. Ono S, Kato M, Imai A, et al. Preliminary tial of rebamipide for prevention of low-dose aspirin-inducedgastric injury in healthy subjects: a randomized, double-blind, placebo-controlled, cross-over study. J Clin Biochem Nutr 2009; 45: 248-253.
12. Lanas A, Polo-Tomas M, Roncales P, Zapardiel J, Gonzalez M, Santos V. Type of prescription and leves adherence to NSAIDs and gastricprotectors in at-risk GI patients. Gastroenterology 2010; 138 (Supple 1): S108.
13. Arakawa T, Fujiwara Y, Sollano JD, et al. A questionnaire-based survey on the prescription of non-steroidal anti-inflammatory drugs by physicians in East Asian countries in 2007. Digestion 2009; 79: 177-185.
14. Kawai T, Yamagishi T, Goto S. Circadian variations of gastrointestinal mucosal damage detected with transnasal endoscopy in apparently healthy subjects treated with low-dose aspirin (ASA) for a short period. J Atheroscler Thromb 2009; 16: 155-163.
15. Poulsom R, Begos DE, Modlin IM. Molecular aspects of restitution: functions of trefoil peptides. Yale J Biol Med 1996; 69: 137-146. (Pubitemid 27172924)
16. Thim L, May FE. Structure of mammalian trefoil factors and functional insights. Cell Mol Life Sci 2005; 62: 2956-2973. (Pubitemid 43004748)
17. Hauser F, Poulsom R, Chinery R, et al. hP1.B, a human P-domain peptide homologous with rat intestinal trefoil factor, is expressed also in the ulcer-associated cell lineage and the uterus. Proc Natl Acad Sci USA 1993; 90: 6961-6965. (Pubitemid 23222368)
18. Vestergaard EM, Poulsen SS, Grønbaek H, et al. Development and evaluation of an ELISA for human trefoil factor 3. Clin Chem 2002; 48: 1689-1695.
19. Vestergaard EM, Brynskov J, Ejskjaer K, et al. Immunoassays of human trefoil factors 1 and 2: measured on serum from patients with inflammatory bowel disease. Scand J Clin Lab Invest 2004; 64: 146-156. (Pubitemid 38491386)
20. Khan Q, Mehta L. Relevance of platelet-independent effects of aspirin to its salutary effect in atherosclerosis-related events. J Atheroscler Thromb 2005; 12: 185-190.
21. Konturek JW, Dembiński A, Konturek SJ, Domschke W. Helicobactor pylori and gastric adaptation to repeated aspirin administration in humans. J Physiol Pharmacol 1997; 48: 383-391. (Pubitemid 27421482)
22. Wong WM, Poulsom R, Whight NA. Trefoil peptide. Gut 1999; 44: 890-895.
23. Hoffmann W, Jagla W. Cell type specific expression of secretary TFF peptides; colocalization with mucins and synthesis in the brain. Int Rev Cytol 2002; 213: 147-181. (Pubitemid 34112918)
24. Rio MC, Bellocq JP, Daniel JY, et al. Brest cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa. Science 1988; 241: 705-708.
25. Tomasetto C, Rio MC, Gautier C, et al. hsp, the domain-duplicated homolog of pS2 protein, is co-expressed with pS2 in stomach but not in brest carcinoma. EMBO J 1990; 9: 407-414.
26. Koitabashi A, Shimada T, Fujii Y, et al. Indometacin up-regulates TFF2 expression in gastric epithelial cells. Aliment Pharmacol Ther 2004; 20 Suppl. 1: 171-176. (Pubitemid 39120290)
27. Alderman BM, Ulaganathan M, Judd LM, et al. Insights into the mechanisms of gastric adaptation to aspirin-induced injury: a role for regenerating protein but not trefoil peptides. Lab Invest 2003; 83: 1415-1425. (Pubitemid 37267825)
28. McKenzie C, Thim L, Parsons ME. Topical and intravenous administration of trefoil factors protect the gastric mucosa from ethanol-induced injury in the rat. Aliment Pharmacol Ther 2000; 14: 1033-1034.
29. Suzuki T, Yoshida N, Nakabe N, et al. Prophylactic effect of rebamipide on aspirin-induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution. J Pharmacol Sci 2008; 106: 469-477. (Pubitemid 351468600)
30. Iijima K, Ichikawa T, Okada S, et al. Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test. Dig Dis Dci 2009; 54: 1500-1507.
31. De Miguel A, Ibanez B, Badimón JJ. Clinical implications of clopidogrel resistance. Thromb Haemost 2008; 100: 196-203.
32. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 26: 195-198. (Pubitemid 351212675)
33. Qiao HL, Hu YR, Tian X, et al. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. Eur J Clin Pharmacol 2006; 62: 107-112.
34. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2004; 5: 181-202. (Pubitemid 38351277)
35. Yamamoto T, Isono A, Mishina Y, et al. Role of gastric mucoprotective drugs: possible effect of rebamipide. J Clin Biochem Nutr 2010; 47: 27-31.
36. Niwa Y, Nakamura M, Ohmiya N, et al. Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study. J Gastroenterol 2008; 43: 270-276. (Pubitemid 351650037)
37. Kawai T, Lanas A, Goto S. European physicians don't like cytoprotective agents? J Clin Biochem Nutr 2011; 49: 67.
38. Johnson DA, Cattau EL Jr., Khan A, Newell DE, Chobanian SJ. Fiberoptic esophagogastroscopy via nasal intubation. Gastrointest Endosc 1987; 33: 32-33. (Pubitemid 17010109)
39. Dumortier J, Ponchon T, Scoazec JY, et al. Prospective evaluation of transnasal esophagogastro-duodenoscopy: feasibility and study on performance and tolerance. Gastrointest Endosc 1999; 49: 285-291. (Pubitemid 29135218)
40. Garcia RT, Cello JP, Nguyen MH, et al. Unsedated ultrathin EGD is well accepted when compared with conventional sedated EGD: a multicenter randomized trial. Gastroenterology 2003; 125: 1606-1612. (Pubitemid 37500424)
41. Kawai T, Miyazaki I, Yagi K, et al. Comparison of the effects on cardiopulmonary function of ultrathin transnasal versus normal diameter trans-oral esophagogastro-duodenoscopy in Japan. Hepatogastroenterology 2007; 54: 770-774. (Pubitemid 46903720)